In another report, Hauschild et al. undertook a randomized multicenter phase III study comparing the anti-melanoma effects of DTIC plus IFN-α with or without IL-2, finding that response rates did not differ between arms [2]. This evidence concerns the gene IFNA2 and melanoma.